Figure 2
From: Acitretin mitigates uroporphyrin-induced bone defects in congenital erythropoietic porphyria models
Acitretin mitigates CEP bone phenotype in zebrafish. (A) 6dpf larvae were injected with uro-I and transferred to medium containing acitretin or DMSO. At 7dpf larvae were injected with calcein and imaged by confocal microscopy. Quantification of porphyrin fluorescence (B), porphyrin excretion (C) and operculum volume (D) from experiment in (A). Symbols represent individual larvae (12–25/group) from 3–4 independent experiments. (E) 6dpf larvae were injected with uro-I. At 7dpf they were transferred to medium containing acitretin or DMSO. At 8dpf larvae were injected with calcein and imaged by confocal microscopy. Quantification of porphyrin fluorescence (F), porphyrin excretion (G) and operculum volume (H) from experiment in (E). Arrowhead-operculum; box-vertebrae (A, E). Symbols represent individual larvae (18–64/group) from 3–4 independent experiments. (I-K) Larvae were treated as in (A) with the indicated retinoid or DMSO and porphyrin fluorescence (I), porphyrin excretion (J) and operculum volume (K) were assayed. Bone volume was normalized to DMSO-treated larvae set to 100%, (D, H, K). Porphyrin excretion was normalized to DMSO-treated larvae set to 100%, (C, G, J). Symbols represent individual larvae (7–44/group) from 2–4 independent experiments. Scale bars: 200 µm. Three-dimensional image reconstruction (A, E) was performed using Imaris 3D software v7.7 (http://imaris.oxinst.com/). *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.
